Counterfeit and Substandard — Cancer Drugs in India

The most reliable check is traceability, not appearance. Verify the batch number on the manufacturer's website or the CDSCO Sugam portal — a genuine batch will return a match with the product name, manufacturer, and expiry. Also check that the Schedule H1 marking is present, the tamper-evident seal is intact, and the medicine was dispensed from a licensed pharmacy against your oncologist's prescription. If any of these checks fail, tell your oncologist before any dose is administered.

Buying chemotherapy online without a verified prescription from a registered medical practitioner is not permitted under Indian law, and the supply chain for online sales is difficult to verify. CDSCO alerts have specifically flagged online platforms as a route for substandard and falsified oncology medicines. The safe route is a licensed hospital pharmacy that sources from an authorised distributor and reconciles each batch against your prescription before dispensing.

A generic medicine is a different thing from a counterfeit. A CDSCO-approved generic contains the same active ingredient, in the same dose and formulation, meeting the same quality standard as the originator brand. A counterfeit is a deliberate fraud: wrong ingredient, wrong amount, or no active ingredient at all. Choosing between a licensed generic and an originator brand is a clinical and financial conversation to have with your oncologist and pharmacist. Accepting medicine from an unverifiable source is the risk, regardless of which name is on the label.

Originator brands carry the cost of original clinical development and the first regulatory approval globally. Licensed generics enter after patent expiry with lower development costs, which is why they are often significantly cheaper. A large difference between an originator and a well-established generic is normal and expected. A price that undercuts even the generic by a substantial margin — particularly from an informal source — is a warning sign, because there is no legitimate cost structure that explains it.

Tell your oncologist the same day, before any further doses are given. Keep the packaging, the vial or box, and any receipt or documentation of where it came from. Your oncologist can report it to CDSCO through the Pharmacovigilance Programme of India and escalate if there is a patient safety concern. Do not return it to the seller or dispose of it yourself before the oncology team has reviewed the situation.

Yes. CDSCO publishes alerts for spurious, substandard, and misbranded medicines and coordinates enforcement with State Drug Controllers. The CDSCO Sugam portal allows batch-number verification for a range of products. Recall orders are issued when a batch fails quality testing. Enforcement is uneven across states and the system is not comprehensive, but documented counterfeits in the Indian market have been actioned. Current drug alerts are published on the official CDSCO website.